We evaluated the assays by measuring the plasma levels of apoAII-isoforms in samples from patients with pancreatic cancer and pancreatic disorders, including precancerous lesions and various malignant diseases of other organs, and we then compared the results with those of healthy controls. This evidence concerns the gene APOA2 and familial pancreatic carcinoma.